1. Home
  2. WALD vs TNXP Comparison

WALD vs TNXP Comparison

Compare WALD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waldencast plc

WALD

Waldencast plc

HOLD

Current Price

$1.93

Market Cap

228.8M

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$17.15

Market Cap

231.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WALD
TNXP
Founded
1988
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.8M
231.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
WALD
TNXP
Price
$1.93
$17.15
Analyst Decision
Strong Buy
Buy
Analyst Count
5
1
Target Price
$4.76
$70.00
AVG Volume (30 Days)
169.5K
639.5K
Earning Date
11-24-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$274,560,000.00
$10,299,000.00
Revenue This Year
$4.61
$14.79
Revenue Next Year
$11.22
$933.49
P/E Ratio
N/A
N/A
Revenue Growth
14.22
N/A
52 Week Low
$1.48
$6.76
52 Week High
$4.10
$72.00

Technical Indicators

Market Signals
Indicator
WALD
TNXP
Relative Strength Index (RSI) 41.56 43.38
Support Level $1.73 $17.71
Resistance Level $2.01 $19.35
Average True Range (ATR) 0.16 1.34
MACD -0.05 0.04
Stochastic Oscillator 25.33 37.55

Price Performance

Historical Comparison
WALD
TNXP

About WALD Waldencast plc

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: